Cellectis to Host Business Update Conference Call on September 14

NEW YORK, Sept. 11, 2026 /CourierPR/ -- Cellectis, a clinical-stage biotechnology company based in Paris, France, with additional offices in New York and Raleigh, North Carolina, is set to host a conference call and webcast on September 14, 2026, to provide a business update. The event will be conducted in two languages, English and French, to cater to a broader audience.

For English-speaking participants, the call will commence at 8:00 a.m. Eastern Time (2:00 p.m. Central European Time). Interested parties can join via the webcast at the following link: viavid.webcasts.com/starthere.jsp?ei=1775356&tp_key=7d1d05c480. Alternatively, they can dial in using the provided numbers: +1 (800) 717 1738 or +1 (646) 307 1865. French-speaking participants are invited to join the call at 9:00 a.m. Eastern Time (3:00 p.m. Central European Time). The webcast for French speakers can be accessed at viavid.webcasts.com/starthere.jsp?ei=1775361&tp_key=2968b7b0ca. The same dial-in numbers will be available for this session.

Cellectis is known for its pioneering gene-editing platform, which it uses to develop life-saving cell and gene therapies. The company is particularly noted for its allogeneic approach in CAR T immunotherapies for oncology, where it aims to create off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. Additionally, Cellectis has a platform for developing gene therapies in other therapeutic areas, leveraging its in-house manufacturing capabilities to control the entire gene therapy value chain from start to finish.

The conference call and webcast are expected to offer insights into the company's recent developments, progress in ongoing clinical trials, and future plans. Investors and stakeholders are encouraged to participate to stay informed about the company's strategic direction and performance.